he total number of shares and votes in Oasmia Pharmaceutical AB (publ) amounts to 105,542,644 as of November 30, 2015. The increase in the number of shares is attributable to the IPO and listing on NASDAQ Capital Markets in the US carried out in October/November 2015, which comprised 7,684,500 shares.
A list of the company principal shareholders will be available at www.vivesto.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM), the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365) and NASDAQ USA (OASM).